Latest News and Press Releases

Dublin, April 17, 2024 (GLOBE NEWSWIRE) -- The "Myasthenia Gravis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's...

NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...

NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...

New York, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Myasthenia Gravis Treatment Market Poised for Steady Growth, driven by Innovation and Rising Awareness The global market for myasthenia gravis (MG)...

Dublin, Dec. 18, 2023 (GLOBE NEWSWIRE) -- The "Global Myasthenia Gravis Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering. The global market for...

Pune, India, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Global Myasthenia Gravis Treatment Market Size was valued at USD 1.15 billion in 2020 and is projected to grow from USD 2.03 billion by 2028 exhibiting...

CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...

New York, USA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Myasthenia Gravis Market is Projected to Boost at a Moderate Growth Rate by 2032, Estimates DelveInsight | Leading Companies - DAS-MG, Catalyst,...